02.05.2024 | Editorial
Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines
verfasst von:
David Groheux, Sofia C. Vaz, Gary A. Ulaner, Gary J. R. Cook, John Patrick Pilkington Woll, Ritse M. Mann, Philip Poortmans, Fatima Cardoso, Heather Jacene, Stephanie L. Graff, Isabel T. Rubio, Marie-Jeanne Vrancken Peeters, Elizabeth H. Dibble, Lioe-Fee de Geus-Oei
Erschienen in:
European Journal of Nuclear Medicine and Molecular Imaging
Einloggen, um Zugang zu erhalten
Excerpt
Breast cancer (BC) is the most commonly diagnosed cancer worldwide. Recently, 2-[
18F]FDG PET/CT has become indispensable in the care of patients with BC. In this issue of the
European Journal of Nuclear Medicine and Molecular Imaging, the Joint EANM-SNMMI guideline on the role of 2-[
18F]FDG PET/CT in no special type breast cancer [
1] is published. This is the first guideline with the nuclear medicine societies’ participation in this topic endorsed by the following relevant societies in this field: the American College of Radiology (ACR), the European Society of Surgical Oncology (ESSO), the European Society for Radiotherapy and Oncology (ESTRO), the European Society of Breast Imaging/European Society of Radiology (EUSOBI/ESR), and the European Society of Breast Cancer Specialists (EUSOMA). In these guidelines, updated information about 2-[
18F]FDG PET/CT procedures is summarized, and the current evidence of the role of 2-[
18F]FDG PET/CT in the initial staging, assessment of treatment response, and assessment of recurrence in patients with BC is presented and organized into recommendation boxes (and summarized in Table 5 of the EANM/SNMMI guidelines). All recommendations were scored in terms of level of evidence and grade of recommendation, with a percentage of agreement of at least 85% by a group multidisciplinary team of experts. Finally, other developments and future applications are discussed [
1]. …